Elise Chong, MD, discusses the rationale for conducting a 4-year analysis of tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Elise Chong, MD, an associate professor of Medicine at the Hospital of the University of Pennsylvania, discusses the rationale for conducting a 4-year analysis of tisagenlecleucel (Kymriah) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
There are positive 2-year data around CD19-directed chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory DLBCL. The phase I/II ZUMA-1 trial (NCT02348216), shows the efficacy and safety of CD19-directed CAR T-cell agent axicabtagene ciloleucel (KTE-C19) in refractory aggressive non-Hodgkin lymphoma, including DLBCL. The phase II JULIET trial showed the efficacy and safety of tisagenlecleucel in patients with relapsed/refractory DLBCL. The criticism around these studies, however, is that the follow-up time was short, Chong says.
The purpose of evaluating and reporting the 4-year outcomes of patients with relapsed/refractory DLBCL is to answer existing questions about the durability of CD19-directed CAR T-cell agents and whether or not there is long-term toxicity in CAR T cells.
The analysis showed that in the 24 patients with heavily pretreated, advanced stage DLBCL, 35% continued to be progression-free at a median follow-up of 49 months. Also, in patients who had a response to therapy, 60% continued responding. The overall survival in these patients was 22 months.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Timing of DLBCL Relapse Linked With Evolutionary Patterns
December 1st 2023A report suggests the cause behind different outcomes among patients with diffuse large B-cell lymphoma who relapse, highlighting that patients whose cancer relapses shortly after treatment tend to have worse responses to additional chemotherapy-based treatment.
Read More
Updated Data Show Efficacy of Tafasitamab/Lenalidomide in R/R DLBCL
November 28th 2023In the first article of a 2-part series, Hayder Saeed, MD, discusses the 5-year follow up data from the L-MIND study, which shows the continuing efficacy of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More